以糖尿病酮症酸中毒为表现的遗传性血色病1例报告
DOI: 10.3969/j.issn.1001-5256.2021.05.040
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:胡滢月、鲁利莎参与病史收集,撰写及修改论文;李贞茂、李良平、雷蕾等负责拟定写作思路,指导撰写文章并最后定稿。
A case of hereditary hemochromatosis with diabetic ketoacidosis as the manifestation
-
-
Key words:
- Hemochromatosis /
- Diabetic Ketoacidosis /
- Diagnosis /
- Therapeutics
-
[1] BACON BR, ADAMS PC, KOWDLEY KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Disease[J]. Hepatology, 2011, 54(1): 328-343. DOI: 10.1002/hep.24330. [2] LUO M, LIU YH, DENG ZB, et al. An excerpt of ACG clinical guideline: Hereditaryhemochromatosis(2019)[J]. J Clin Hepatol, 2020, 36(1): 53-56. DOI: 10.3969/ j.issn.1001-5256.2020.01.011.罗敏, 刘一涵, 邓泽彬, 等. 《2019美国胃肠病学院临床实践指南: 遗传性血色素沉着》摘译[J]. 临床肝胆病杂志, 2020, 36(1): 53-56. DOI: 10.3969/ j.issn.1001-5256.2020.01.011. [3] GUAN Y, AN P, ZHANG ZZ, et al. Advances in pathophysiology, diagnosis and management of hereditary hemochromatosis[J]. Chin Bull Life Sci, 2012, 24(8): 775-784. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX201208009.htm管宇, 安鹏, 张竹珍, 等. 血色病的临床与基础研究进展[J]. 生命科学, 2012, 24(8): 775-784. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX201208009.htm [4] WANG XL. CT and MRI Manifestations of hemochromatosis[J]. J Imag Res Med Appl, 2019, 3(15): 57-58. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY201915030.htm王秀兰. 血色病的CT及MRI表现[J]. 影像研究与医学应用, 2019, 3(15): 57-58. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY201915030.htm [5] MILITARU MS, POPP RA, TRIFA AP. Homozygous G320V mutation in the HJV gene causing juvenile hereditary haemochromatosis type A. A case report[J]. J Gastrointestin Liver Dis, 2010, 19(2): 191-193. http://www.ncbi.nlm.nih.gov/pubmed/20593054 [6] LI YF, ZHANG HX, ZHANG HT, et al. Mutation analysis of the pathogenic gene in a Chinese family with hereditary haemochromatosis[J]. Hereditas, 2014, 36(11): 1152-1158. DOI: 10.3724/ SP.J.1005.2014.1152.李元丰, 张红星, 张海涛, 等. 一个中国遗传性血色病家系致病基因的突变分析[J]. 遗传, 2014, 36(11): 1152-1158. DOI: 10.3724/SP.J.1005.2014.1152. [7] de GOBBI M, ROETTO A, PIPERNO A, et al. Natural history of juvenile haemochromatosis[J]. Br J Haematol, 2002, 117(4): 973-979. DOI: 10.1046/j.1365- 2141.2002.03509.x. [8] XU P, ZHOU YD, LI Y. Observation of curative effect of blood-letting therapy in patients with primary hemochromatosis[J]. J Clin Hematol, 2008, 21(12): 640-641. DOI:10.3969/j.issn. 1004-2806-B.2008.06.007.徐朴, 周佑德, 李艳. 原发性血色病患者放血疗法疗效观察[J]. 临床血液学杂志, 2008, 21(12): 640-641. DOI:10.3969/j.issn. 1004-2806-B.2008.06.007. [9] LIU RR. Overview of iron overload and the new iron chelator deferasirox[J]. Chin J New Drugs, 2011, 20(22): 2177-2180. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201122002.htm刘容容. 铁过载概述及口服祛铁新药地拉罗司[J]. 中国新药杂志, 2011, 20(22): 2177-2180. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201122002.htm [10] LYU TX, ZHANG W, LI XJ, et al. Characteristics of genemutation in Chinese patients with hereditary hemochromatosis[J]. J Clin Hepatol, 2016, 32(8): 1571-1574. DOI: 10.3969/ j.issn.1001-5256.2016.08.028.吕婷霞, 张伟, 李潇瑾, 等. 我国人群遗传性血色病基因突变特点分析[J]. 临床肝胆病杂志, 2016, 32(8): 1571-1574. DOI: 10.3969/ j.issn.1001-5256.2016.08.028.